Peptide Comparison
GHRP-6 vs Tesamorelin + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHRP-6 | Tesamorelin + Ipamorelin | |
|---|---|---|
| Class | GHRP; ghrelin receptor agonist | FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | GHS-R1a agonist with strong orexigenic effect | Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. |
| Route | SC / Intranasal | SC injection |
| Half-life | ~15-30 min | Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs |
| Dosage (research) | 100-300 mcg SC 2-3x daily | 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off |
| Evidence tier | Anecdotal + Animal Studies | FDA-Approved (component) |
| Research depth | 163 indexed | — |
| Availability | Research Chemical | Compounding Restricted |
| Reported risks | Strong hunger; cortisol/prolactin rise; water retention | Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHRP-6 or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has stronger documented evidence (FDA-Approved (component)) than GHRP-6 (Anecdotal + Animal Studies) while both occupy the ghrp / gh-secretagogue classes. When clinical-evidence tier is the deciding factor, Tesamorelin + Ipamorelin is the safer pick. GHRP-6 may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHRP-6 and Tesamorelin + Ipamorelin?
GHRP-6 is classed as GHRP; ghrelin receptor agonist; Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: GHRP-6, GHS-R1a agonist with strong orexigenic effect; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: GHRP-6, ~15-30 min; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: GHRP-6, SC / Intranasal; Tesamorelin + Ipamorelin, SC injection.
Which has stronger evidence, GHRP-6 or Tesamorelin + Ipamorelin?
Tesamorelin + Ipamorelin has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHRP-6 is graded Anecdotal + Animal Studies, with 7 cited sources on its reference page and 163 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.
Which is more accessible, GHRP-6 or Tesamorelin + Ipamorelin?
Neither GHRP-6 nor Tesamorelin + Ipamorelin is an FDA-approved drug. Catalog status: GHRP-6, Research Chemical; Tesamorelin + Ipamorelin, Compounding Restricted. FDA lists GHRP-6 in category 2 of its bulk-substance compounding policy (503B, added September 29, 2023).
Are GHRP-6 and Tesamorelin + Ipamorelin ever combined?
GHRP-6 and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…